Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2012 by Campus Bio-Medico University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Patti Giuseppe, Campus Bio-Medico University Identifier:
First received: April 3, 2012
Last updated: April 4, 2012
Last verified: April 2012

Patients who developed an acute coronary syndrome despite dual antiplatelet therapy with aspirin and clopidogrel may benefit from a further dose of clopidogrel before a percutaneous coronary intervention.

The aim of this study is to evaluate safety and effectiveness of clopidogrel reloading in patients on chronic clopidogrel therapy with acute coronary syndrome undergoing percutaneous coronary intervention.

Condition Intervention Phase
Acute Coronary Syndrome
Myocardial Infarction
Drug: Clopidogrel
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial.

Resource links provided by NLM:

Further study details as provided by Campus Bio-Medico University:

Primary Outcome Measures:
  • Major Adverse Cardiovascular Events [ Time Frame: 30 days ]
    Death Myocardial Infarction Target Vessel Revascularization

Secondary Outcome Measures:
  • Bleeding Events [ Time Frame: 30 days ]
    Occurrence of vascular/bleeding complications, defined as: (a) major bleeding (intracranial bleeding or clinically overt bleeding associated with a decrease in haemoglobin >5 g/dL, according to the TIMI criteria); (b) minor bleeding (clinically overt haemorrhage associated with a fall in haemoglobin ≤5 g/dL); (c) entry-site complications (haematoma >5 cm, pseudoaneurysm or arteriovenous fistula)

  • Grade of platelet residual reactivity [ Time Frame: Immediately before PCI (4-6h after randomization), 8h and 24h after PCI ]

    Patient's response to clopidogrel at 3 different timing, assessed with VerifyNow P2Y12 Assays.

    The first timing is immediately before PCI (4-6h after randomization), once accomplished the diagnostic angiogram.

    The second and third timings are, respectively, 8h and 24h after PCI.

Estimated Enrollment: 240
Study Start Date: November 2011
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Reload
600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
Drug: Clopidogrel
600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
Other Name: Plavix
Placebo Comparator: Placebo
Placebo arm in addition to the chronic daily dose of 75 mg
Drug: Placebo
Placebo in addition to the chronic daily dose of 75 mg


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • chronic (> 10 days) therapy with clopidogrel (75 mg/day)
  • non-ST-segment elevation acute coronary syndrome (ACS) requiring early diagnostic angiography

Exclusion Criteria:

  • primary percutaneous coronary intervention (PCI) for acute ST-segment elevation acute myocardial infarction
  • platelet count < 70 × 10^9/L
  • high bleeding risk
  • coronary bypass grafting in the previous 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01572129

Contact: Giuseppe Patti, MD 06225411899

Vito Fazzi Hospital Recruiting
Lecce, Italy, 73100
Principal Investigator: Giuseppe Colonna, MD         
Sub-Investigator: Antonio Montinaro, MD         
Campus Bio-Medico University Recruiting
Rome, Italy, 00128
Principal Investigator: Giuseppe Patti, MD         
Sub-Investigator: Vincenzo Vizzi, MD         
Sub-Investigator: Elisabetta Ricottini, MD         
Sub-Investigator: Fabio Mangiacapra, MD         
Sponsors and Collaborators
Campus Bio-Medico University
Principal Investigator: Giuseppe Patti, MD Campus Bio-Medico University
  More Information

Responsible Party: Patti Giuseppe, MD, FACC, Co-Chair of the ARMYDA Study Group, Assistant Professor of Cardiology, Campus Bio-Medico University Identifier: NCT01572129     History of Changes
Other Study ID Numbers: 2011-005449-11
Study First Received: April 3, 2012
Last Updated: April 4, 2012

Additional relevant MeSH terms:
Myocardial Infarction
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Fibrinolytic Agents
Fibrin Modulating Agents
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on April 21, 2017